GPT Healthcare Limited has outlined a confident FY27 growth roadmap in its post-results management concall, guiding for 15% year-on-year revenue growth and EBITDA margin expansion of approximately 100 basis points to around 20.2% — driven by tariff increases, specialty optimisation across its Kolkata units, and the ramp-up of its Raipur greenfield hospital toward operational breakeven.
The company’s Average Revenue Per Occupied Bed — the primary revenue intensity metric for hospital businesses — is expected to grow approximately 8% in FY27, driven by a combination of tariff hikes across its network and a deliberate shift toward higher-value specialty care. The Agartala unit is expected to see ARPOB grow by 7-8% in FY27, though it will continue to operate at a lower ARPOB than the Kolkata units — Salt Lake and Dum Dum — reflecting the different payer mix, specialty depth, and market positioning of the Tripura facility relative to the company’s core West Bengal operations.
Occupancy targets for FY27 are specific and ambitious across the network. Salt Lake — GPT Healthcare’s flagship facility — is targeted at 70-73% occupancy, while Dum Dum is targeted at 72-78%. Agartala is expected to move toward 58% occupancy as the facility deepens its catchment penetration in Tripura and the surrounding northeast region. The newly commissioned Howrah facility is targeted to reach the late 50s in occupancy by the end of FY27 — a ramp-up trajectory consistent with a hospital in its early operational phase building out its specialist base and patient referral network.
The Raipur hospital — GPT Healthcare’s eastern India expansion beyond its core West Bengal and northeast footprint — is projected to reach monthly operational breakeven by Q3FY27, closing the full year at around 30% occupancy. Management acknowledged that the full-year FY27 outcome for Raipur will show a slight loss before the facility turns fully positive in FY28, as the breakeven is achieved partway through the year rather than from the start. The Raipur ramp-up narrative is familiar for hospital businesses — new facilities in non-home markets typically require 18-36 months to reach mature occupancy levels as specialist recruitment, patient awareness, and insurer panel empanelment build progressively.
The Jamshedpur hospital — a 150-bed greenfield facility — is expected to be commissioned by Q4FY27, with a capital expenditure of approximately ₹70 lakh per bed. Management indicated the Jamshedpur facility will follow a similar ramp-up trend as Raipur — implying a multi-quarter journey from commissioning to breakeven occupancy, with full-year profitability expected in FY29 at the earliest under a conservative scenario. The ₹70 lakh per bed capex — which translates to approximately ₹105 crore total for the 150-bed facility — is in line with mid-tier hospital construction costs in Tier-2 Indian cities.
GPT Healthcare’s FY27 guidance positions the company as a mid-sized multi-location hospital chain executing a deliberate geographic expansion strategy beyond its core Kolkata stronghold — a template being followed by several regional hospital operators who are using their home market profitability to fund greenfield expansion in underserved Tier-2 and Tier-3 cities across eastern and central India. The Raipur-Jamshedpur expansion corridor reflects the company’s thesis that GPT’s clinical brand, developed in the competitive Kolkata market, can be transplanted into cities with lower hospital density and significant unmet demand for quality secondary and tertiary care.
The 100 basis point EBITDA margin expansion to 20.2% — if delivered — would represent a meaningful improvement in profitability even as new hospitals in Raipur and Jamshedpur dilute consolidated margins in their early ramp phases. The guidance implies that the maturing Kolkata and Agartala units are expected to deliver sufficiently strong margin improvement to more than offset the new hospital drag — a sign of management’s confidence in the operating leverage embedded in its established facilities.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making investment decisions.